Literature DB >> 33628294

Effect of Traditional Chinese Medicine Poge Heart-Saving Decoction on Cardiac Function in Heart Failure Rat Model.

Lei Liu1, Yanfei Mo2, Bingying Wu3, Zongliang Yu3, Bugao Sun1.   

Abstract

BACKGROUND: Poge heart-saving decoction (PHSD) has been used as a medicine treating heart failure in China for many years. The study aimed to explore the effect of PHSD on cardiac function in heart failure conditions and its underlying mechanism.
METHODS: Adriamycin was used to induce the model of heart failure (HF) in rats. Sixty rats were randomly divided into six groups: blank control group, sham group, 9.33 g/kg group (low-PHSD, test group), 13.995 g/kg group (moderate-PHSD, test group), 18.66 g/kg group (high-PHSD, test group), and fosinopril group (4.67 mg/kg, comparison test group). Cardiac ultrasound was used to evaluate the cardiac function of the rats, and radioimmunoassay was used to measure aldosterone (ALD) and angiotensin II (AngII) levels in the serum.
RESULTS: Compared with the blank control group, the left ventricular end-diastolic dimension (LVEDd) and left ventricular end-systolic dimension (LVEDs) in the sham group were increased (1.04 ± 0.12 vs. 0.67 ± 0.13 cm; 0.75 ± 0.13 vs. 0.28 ± 0.10 cm; P < 0.05), and the left ventricular ejection fraction was decreased (36.65 ± 5.74 vs. 76.09 ± 4.23%; P < 0.05). The ejection fraction of HF rats was increased in 9.33 g/kg group, 13.995 g/kg group, and 18.66 g/kg group compared with those of the sham group (57.13 ± 1.63, 58.43 ± 1.98, and 59.21 ± 1.37 vs. 36.65 ± 5.74%; P < 0.05). PHSD also improved cardiac function by reducing the LVEDd and LVEDs (0.88 ± 0.11, 0.75 ± 0.13, and 0.72 ± 0.18 vs. 1.04 ± 0.12 cm; 0.62 ± 0.10, 0.63 ± 0.17, and 0.45 ± 0.11 vs. 0.75 ± 0.13 cm; P < 0.05). The levels of ALD and AngII in the serum of rats in the sham group were significantly higher than those in the blank control group (371.58 ± 39.25 vs. 237.12 ± 17.35 μg/L; 232.18 ± 16.33 vs. 159.44 ± 18.42 pg/L; P < 0.05). The ALD and AngII of the rats in all of the three PHSD groups and the fosinopril group were decreased (276.81 ± 25.63, 277.18 ± 21.35, 268.19 ± 19.28, and 271.47 ± 28.96 vs. 371.58 ± 39.25 μg/L; 169.41 ± 27.53, 168.81 ± 19.78, 164.23 ± 21.34, and 174.27 ± 22.84 vs. 232.18 ± 16.33 pg/L; P < 0.05). The histopathological changes of the myocardium in the sham group showed the disorganized fiber, shaded staining, fracture, and zonation. The fracture of the myocardium was relieved in all groups except the sham group and the blank control group.
CONCLUSION: Therefore, PHSD could shorten LVEDd and LVEDs of rats and reverse ventricular remodeling. The mechanism might be related to the inhibition of the activation level of renin-angiotensin-aldosterone system (especially ALD and AngII) and decreasing the postload of the heart.
Copyright © 2020 Lei Liu et al.

Entities:  

Year:  2020        PMID: 33628294      PMCID: PMC7895586          DOI: 10.1155/2020/8762509

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN: 1741-427X            Impact factor:   2.629


  30 in total

1.  The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation.

Authors:  Georg Nickenig; David G Harrison
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Altered expression of c-kit and nanog in a rat model of Adriamycin-induced chronic heart failure.

Authors:  Shuo Li; Kang Guo; Junfang Wu; Zhikun Guo; Airong Li
Journal:  Am J Cardiovasc Dis       Date:  2017-04-15

Review 3.  Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms.

Authors:  Luc Rochette; Charles Guenancia; Aurélie Gudjoncik; Olivier Hachet; Marianne Zeller; Yves Cottin; Catherine Vergely
Journal:  Trends Pharmacol Sci       Date:  2015-04-17       Impact factor: 14.819

Review 4.  Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention.

Authors:  Krishnaswami Vijayaraghavan; Prakash Deedwania
Journal:  Cardiol Clin       Date:  2011-02       Impact factor: 2.213

5.  Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.

Authors:  U P Jorde; P V Ennezat; J Lisker; V Suryadevara; J Infeld; S Cukon; A Hammer; E H Sonnenblick; T H Le Jemtel
Journal:  Circulation       Date:  2000-02-29       Impact factor: 29.690

Review 6.  Treatment of heart failure with fosinopril: an angiotensin converting enzyme inhibitor with a dual and compensatory route of excretion.

Authors:  G Mancia; C Giannattasio; G Grassi
Journal:  Am J Hypertens       Date:  1997-10       Impact factor: 2.689

7.  Total triterpene acids, active ingredients from Fructus Corni, attenuate diabetic cardiomyopathy by normalizing ET pathway and expression of FKBP12.6 and SERCA2a in streptozotocin-rats.

Authors:  Min-You Qi; Hao-Ran Liu; De-Zai Dai; Na Li; Yin Dai
Journal:  J Pharm Pharmacol       Date:  2008-12       Impact factor: 3.765

8.  Therapeutic effects of higenamine combined with [6]-gingerol on chronic heart failure induced by doxorubicin via ameliorating mitochondrial function.

Authors:  Jianxia Wen; Lu Zhang; Jian Wang; Jiabo Wang; Lifu Wang; Ruilin Wang; Ruisheng Li; Honghong Liu; Shizhang Wei; Haotian Li; Wenjun Zou; Yanling Zhao
Journal:  J Cell Mol Med       Date:  2020-02-19       Impact factor: 5.310

9.  The atheroprotective roles of heart-protecting musk pills against atherosclerosis development in apolipoprotein E-deficient mice.

Authors:  Li Lu; Yating Qin; Chen Chen; Xinxin Zhang; Xiangyu Xu; Chao Lv; Xiaoning Wan; Weibin Ruan; Xiaomei Guo
Journal:  Ann Transl Med       Date:  2019-12

10.  Anti-inflammatory effects of the chinese herbal formula sini tang in myocardial infarction rats.

Authors:  Jiangang Liu; Karoline Peter; Dazhuo Shi; Lei Zhang; Guoju Dong; Dawu Zhang; Heimo Breiteneder; Rudolf Bauer; Johannes Jakowitsch; Yan Ma
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-03       Impact factor: 2.629

View more
  2 in total

Review 1.  Cellular and Molecular Mechanism of Traditional Chinese Medicine on Ventricular Remodeling.

Authors:  Yong-Chun Zhu; Bo Liang; Ning Gu
Journal:  Front Cardiovasc Med       Date:  2021-12-01

Review 2.  Mechanism of tonifying-kidney Chinese herbal medicine in the treatment of chronic heart failure.

Authors:  Lizhen Chen; Dayun Yu; Shuang Ling; Jin-Wen Xu
Journal:  Front Cardiovasc Med       Date:  2022-09-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.